SI-BONE to Present at Morgan Stanley 23rd Global Healthcare Conference on September 9, 2025
SI-BONE (Nasdaq: SIBN), a medical device company focused on sacropelvic disorders, will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference in New York. The company's management will conduct a fireside chat on September 9, 2025, at 4:00 AM PT / 7:00 AM ET.
Investors can access the presentation through registration, and a live webcast will be available on SI-BONE's investor relations website. The webcast recording will remain accessible for at least 90 days following the event.
SI-BONE (Nasdaq: SIBN), azienda di dispositivi medici specializzata nei disturbi sacropelvici, parteciperà al Morgan Stanley 23rd Annual Global Healthcare Conference a New York. Il management terrà un fireside chat il 9 settembre 2025 alle 4:00 PT / 7:00 ET.
Gli investitori potranno seguire la presentazione previa registrazione; sarà inoltre disponibile un webcast in diretta sul sito per gli investor relations di SI-BONE. La registrazione del webcast resterà accessibile per almeno 90 giorni dopo l'evento.
SI-BONE (Nasdaq: SIBN), compañía de dispositivos médicos centrada en trastornos sacropélvicos, participará en la Morgan Stanley 23rd Annual Global Healthcare Conference en Nueva York. La dirección ofrecerá un fireside chat el 9 de septiembre de 2025 a las 4:00 PT / 7:00 ET.
Los inversores podrán acceder a la presentación registrándose; habrá además una transmisión en vivo (webcast) disponible en la web de relaciones con inversionistas de SI-BONE. La grabación del webcast permanecerá disponible al menos 90 días tras el evento.
SI-BONE (Nasdaq: SIBN)은 천골·장골 부위 질환(sacropelvic disorders)에 주력하는 의료기기 회사로, 뉴욕에서 열리는 Morgan Stanley 23rd Annual Global Healthcare Conference에 참가합니다. 회사 경영진은 2025년 9월 9일 04:00 PT / 07:00 ET에 파이어사이드 챗을 진행합니다.
투자자는 등록을 통해 발표 자료에 접속할 수 있으며, SI-BONE의 IR 사이트에서 라이브 웨비캐스트가 제공됩니다. 웨비캐스트 녹화본은 행사 종료 후 최소 90일간 다시보기로 제공됩니다.
SI-BONE (Nasdaq: SIBN), une société de dispositifs médicaux spécialisée dans les troubles sacro-pelviens, participera à la Morgan Stanley 23rd Annual Global Healthcare Conference à New York. La direction tiendra un fireside chat le 9 septembre 2025 à 04:00 PT / 07:00 ET.
Les investisseurs pourront accéder à la présentation en s'inscrivant ; un webcast en direct sera également disponible sur le site des relations investisseurs de SI-BONE. L'enregistrement du webcast restera accessible pendant au moins 90 jours après l'événement.
SI-BONE (Nasdaq: SIBN), ein Medizintechnikunternehmen mit Fokus auf sakropelvine Erkrankungen, wird an der Morgan Stanley 23rd Annual Global Healthcare Conference in New York teilnehmen. Das Management führt am 9. September 2025 um 04:00 PT / 07:00 ET ein Fireside-Chat durch.
Investoren können die Präsentation nach Registrierung abrufen; zudem wird ein Live-Webcast auf der Investor-Relations-Website von SI-BONE verfügbar sein. Die Aufzeichnung des Webcasts bleibt mindestens 90 Tage nach der Veranstaltung zugänglich.
- None.
- None.
SANTA CLARA, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming Morgan Stanley 23rd Annual Global Healthcare Conference in New York, NY. Management will be hosting a fireside chat on Tuesday, September 9, 2025, at 4:00 a.m. Pacific Time/ 07:00 a.m. Eastern Time.
Investors interested in listening to the conference call may do so by registering at this link: Morgan Stanley 23rd Global Healthcare Conference. Live audio of the webcast will be available on the “Investors” section of the company’s website at: www.si-bone.com. The webcast will be archived and available for replay for at least 90 days after the event.
About SI-BONE, Inc.
SI-BONE (NASDAQ: SIBN) is a global leader in developing unique technologies for surgical treatment of sacropelvic disorders. Since pioneering minimally invasive SI joint surgery in 2009 with the iFuse Implant System®, SI-BONE has supported over 4,600 physicians in performing a total of nearly 130,000 procedures. A unique body of clinical evidence supports the use of SI-BONE’s technologies with over 175 peer reviewed publications including four randomized controlled trials. SI-BONE has leveraged its leadership in minimally invasive SI joint fusion to commercialize novel solutions for adjacent markets, including adult deformity, spinopelvic and sacropelvic fixation and pelvic trauma.
For additional information on the company or the products, including risks and benefits, please visit www.si-bone.com.
SI-BONE, Sacropelvic Solutions, iFuse Implant System®, iFuse Bedrock Granite, and iFuse TORQ, are registered trademarks, and iFuse 3D, iFuse TORQ TNT, and iFuse INTRA are trademarks of SI-BONE, Inc. ©2025 SI-BONE, Inc. All Rights Reserved.
Investor Contact: Saqib Iqbal investors@si-bone.com
FAQ
When is SI-BONE (SIBN) presenting at the Morgan Stanley Healthcare Conference 2025?
How can investors access SI-BONE's (SIBN) Morgan Stanley conference presentation?
How long will SI-BONE's (SIBN) Morgan Stanley conference presentation be available for replay?
What type of medical devices does SI-BONE (SIBN) specialize in?
